A Nepali surgeon realized the bottleneck in curing blindness wasn't the surgery at all, it was a single imported piece of plastic

the problem

Cataracts were the world's leading cause of preventable blindness, and delivering the surgery at scale in a poor country like Nepal seemed to require importing an artificial lens priced for Western healthcare budgets — a single small plastic component that could cost more than $200, dwarfing every other cost in an otherwise fast, low-tech operation.

background

what everyone would do

Negotiate bulk discounts with Western lens manufacturers, or raise donor funding to subsidize the cost of importing lenses at their existing price — the standard response when a needed input is priced out of reach. It fails at real scale because the import price reflects a market and cost structure built for wealthy healthcare systems, and no amount of negotiation or one-time donor money changes that price permanently or lets the program grow past what donors are willing to keep re-funding every year.

what they saw

Ruit and Hollows saw that the surgery's affordability problem had already been solved on the labor side — the small-incision technique made the surgeon's time cheap and fast — which meant the entire remaining cost problem was concentrated in one purchased object: an imported lens priced for a market Nepal wasn't part of. A lens is a comparatively simple manufactured component, not an irreproducible technology; if Nepal could make an equivalent one domestically, the price would reflect Nepal's manufacturing cost, not a Western retail markup, and the whole economics of the surgery would move at once.

the move

The Tilganga lab began producing its own polymethyl-methacrylate intraocular lenses in Kathmandu rather than importing them, manufacturing the identical functional component the surgery needed at a fraction of the import price, without altering the surgical technique, the surgeon, or the clinical target the lens had to meet.

why it works

An imported lens's price bundles manufacturing cost with brand markup, international shipping, and margins set for wealthy clinical markets that have nothing to do with what the physical component costs to produce; polymethyl-methacrylate lens fabrication itself does not require capabilities Nepal couldn't build with outside engineering help and one dedicated facility. Once that facility existed, every lens implanted no longer carried the imported markup, and because the lens had been the dominant cost in an already-fast, already-cheap surgical procedure, this single substitution collapsed the total cost of the operation by an order of magnitude without requiring any change to who performed the surgery or how.

the payoff

The lens's cost fell from over $200 imported to as little as $7 domestically manufactured, and total surgery cost (lens included) came down to under $20 per case in Ruit's own published series — a roughly 90%+ collapse in the single largest cost driver in the operation. Clinical outcomes did not suffer: Ruit's 1999 peer-reviewed series reported zero major surgical complications at the Tilganga centre and best-corrected vision of 20/60 or better in the large majority of patients at two months, matching results reported for far more expensive Western procedures. The lab now produces roughly 250,000 lenses a year, has distributed more than eight million since opening, and supplies over 50 countries.

where it breaks

It requires enough sustained surgical volume to justify a factory's capital cost, and a component simple enough to manufacture locally to spec without capabilities or raw materials the country genuinely lacks — a component with a real patent wall, exotic manufacturing process, or scarce raw-material dependency won't yield to the same fix. It also depends on credible quality certification: a cheaper locally-made version that clinicians or patients don't trust to match the imported original's safety record loses the point of making it at all, since the whole model rests on proving, with outcomes data, that the substitution cost nothing in quality.

what came after

The Tilganga/Fred Hollows lens lab became a reference model cited alongside India's Aurolab (Aravind Eye Care's own manufacturing arm, founded 1992) in international eye-health literature as proof that local manufacture of a single overpriced input, not fundraising or price negotiation, was the lever that made mass-scale cataract surgery affordable across the developing world; Ruit's small-incision technique paired with locally-made lenses is now taught in US medical schools.

references

1. [1]Low-cost high-volume extracapsular cataract extraction with posterior chamber intraocular lens implantation in NepalOphthalmology (journal), via PubMed, 1999pubmed.ncbi.nlm.nih.gov
2. [2]How Fred Hollows helped make cataract surgery more affordableThe Fred Hollows Foundation NZ, 2023hollows.org.nz
3. [3]High Quality Low Cost Intraocular Lenses (IOLs)Community Eye Health Journal, International Centre for Eye Health (LSHTM), 2000archive.cehjournal.org

keep it

same kind of clever

• 2009 · Airbnb (Brian Chesky, Joe Gebbia)Airbnb's New York bookings weren't stalled by its algorithm — they were stalled by bad photos, so the founders rented a camera and fixed the listings by hand, one apartment at a time.
• 2012 · Buc-ee'sBuc-ee's turned the gas station bathroom — the part every competitor treats as pure cost — into the actual reason to stop there
• 2006 · Cedars-Sinai Medical CenterCedars-Sinai got doctors to wash their hands by photographing the bacteria growing on their own palms